The role of Insulin-like Growth Factor 1, Receptor Activator for Nuclear Factor κB ligand - Osteoprotegerin system, Interleukin 6 and 1\beta in post-transplantation bone metabolic disease in childhood by Wędrychowicz, Anna et al.
248
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.2013.0001
Tom/Volume 64; Numer/Number 4/2013
ISSN 0423–104X
Anna Wędrychowicz, M.D., Ph.D., Department of Paediatric and Adolescent Endocrinology, Polish-American Children’s Institute, Medical College, 
Jagiellonian University, Wielicka St. 265, 30–663 Krakow, Poland, tel.: +48 12 658 12 77, fax: ++48 12 658 10 05, e-mail: anna.wedrychowicz@uj.edu.pl
The role of Insulin-like Growth Factor 1, Receptor Activator 
for Nuclear Factor κB ligand — Osteoprotegerin system, 
Interleukin 6 and 1β in post-transplantation bone metabolic 
disease in childhood
Rola insulinopodobnego czynnika wzrostowego 1, systemu ligand aktywatora 
receptora jądrowego czynnika κB — osteoprotegeryna, interleukina 6 i 1β  
w potransplantacyjnej metabolicznej chorobie kości u dzieci i młodzieży
Anna Wędrychowicz1, 2, Krystyna Sztefko3, Marcin Majka2, Mariusz Z. Ratajczak4
1Department of Paediatric and Adolescent Endocrinology, Chair of Paediatrics, Polish-American Paediatric Institute, Medical College, 
Jagiellonian University in Krakow, Poland 
2Department of Transplantation, Polish-American Paediatric Institute, Medical College, Jagiellonian University in Krakow, Poland  
3Department of Clinical Biochemistry, Polish-American Paediatric Institute, Medical College, Jagiellonian University in Krakow, 
Poland 
4Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA
Abstract
Introduction: Bone disorders observed commonly after haematopoietic stem cells transplantation (HSCT) can be caused by several factors, 
but their detailed pathomechanism is still not well known, especially in childhood. 
The aim of this study was to evaluate: IGF-I, RANKL-OPG system, IL-6, and IL1β levels and their association with bone mineral density 
(BMD) in children and adolescents after HSCT. 
Material and methods: Thirty five patients after allogeneic (N = 21) and autologous (N = 14) HSCT, mean age 8.48 ± 5.18 years, were 
included in the study. Blood samples were taken before HSCT, on the transplantation day, three and six months after HSCT, then each 
year after HSCT for 2–8 years. RANKL, OPG, and IL-1β, IGF-1, and IL-6 were measured by immunochemistry. Total BMD was evaluated 
six months after HSCT using dual energy X-ray absorptiometry, then annually. 
Results: All Z-core values for BMD were negative in all patients. It was significantly higher in patients after auto HSCT than after allo HSCT. 
Serum levels of IGF-1 and IL-6 significantly changed after HSCT. IGF-I levels started to increase in the second year after transplantation. 
IL-6 increased up to 12 months after transplantation. Dynamic although not significant changes of OPG and RANKL levels were observed 
after HSCT. RANKL and IGF-1 values correlated with BMD. IL-6 correlated positively with IL-1β but both did not correlate with BMD. 
Conclusions: Our data indicates that factors influencing bone remodelling change dynamically in the post-transplantation pe-
riod. It suggests that serum RANKL and IGF-1 levels could be markers of bone metabolism after HSCT in paediatric patients. 
(Endokrynol Pol 2013; 64 (4): 248–254)
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Streszczenie
Wstęp: Znanych jest kilka czynników mogących mieć wpływ na zaburzenia kostne obserwowane często po przeszczepieniu komórek 
krwiotwórczych (PKK). Ich dokładna etiopatogeneza pozostaje jednak wciąż nie znana, szczególnie u pacjentów po PKK przebytym w 
dzieciństwie. Celem pracy była ocena surowiczych stężeń: IGF-1, RANKL, OPG, IL-6 i IL1β oraz ich korelacji z gęstością mineralną kości 
(BMD) u dzieci i młodzieży po PKK.
Materiał i metody: Do badań włączono 35 pacjentów w średnim wieku 8,48 ± 5,18 lat po allogenicznych (N = 21) i autologicznych (N = 14) 
PKK. Próbki krwi pobierano przed PKK, w dniu transplantacji, 3 i 6 miesięcy po PKK, a następnie co rok przez 2–8 lat. Stężenia IGF-1, 
RANKL, OPG, IL-1β, IL-6 oznaczane były metodami immunochemicznymi. BMD całego ciała oceniane było metodą DEXA (dual-energy 
X-ray absorptiometry) 6 miesięcy po PKK, a następnie co rocznie. 
Wyniki: Stwierdzono ujemne wartości Z-core dla BMD u wszystkich pacjentów. Były one znacząco wyższe u pacjentów po autologicznych 
niż po allogenicznych PKK. Surowicze stężenia IGF-1 i IL-6 znamiennie zmieniały się w czasie po PKK. Stężenia IGF-1 wzrastały od 2. 
roku po PKK, zaś IL-6 narastały do 12. miesiąca po PKK. Obserwowano również dynamiczne, chociaż nieznamienne zmiany stężeń OPG i 
RANKL po PKK. Wykazano korelacje RANKL i IGF-1 z BMD. IL-6 korelowała pozytywnie z IL-1β, obie interleukiny nie korelowały z BMD. 
Wnioski: Stwierdzono istotne i dynamiczne zmiany czynników mogących mieć wpływ na metabolizm kostny po transplanta-
cji. Sugeruje się, że surowicze stężenia RANKL i IGF-1 mogą być markerami metabolizmu kostnego po PKK u dzieci i młodzieży. 
(Endokrynol Pol 2013; 64 (4): 248–254)
Słowa kluczowe: system RANKL-OPG, IGF-1, interleukiny, potransplantacyjna choroba metaboliczna kości, dzieci i młodzież
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Introduction
Since the end of the 20th century, the number of allo-
geneic and autologous haematopoietic stem cell trans-
plantations (HSCT) performed for malignant and non-
malignant disorders has increased steadily [1]. With less 
early mortality and more widespread use of HSCT, the 
number of long-term survivors will continue to grow. 
Likewise, many children are now surviving HSCT and 
require structured long-term follow-up care to evaluate 
risk factors of post-transplantation complications and to 
provide appropriate prevention and treatment. One of 
the most frequent long-term complications after HSCT 
is transplantation bone disease associated with bone 
turnover abnormalities [2]. 
Based on dual-energy X-ray absorptiometry, more 
than half of long-term survivors show bone loss after 
HSCT [3–5]. Some factors influencing bone remodelling 
after transplantation like hypogonadism, glucocorti-
coid exposure, use of calcineurin inhibitors, secondary 
hyperparathyroidism, hyperthyroidism, and calcium 
and/or vitamin D deficiency, are already known [6–8]. 
However, the detailed mechanism of bone metabo-
lism disorders is not exactly understood, especially in 
children and adolescents. IGF-I, which dynamically 
changes during childhood, plays a role in increasing 
bone mass by influencing osteoblasts’ maturation and 
function [9]. It has been shown that circulating IGF-1 
directly regulates not only bone growth but also bone 
density [10]. Significant correlations between bone 
mineral density (BMD) and serum IGF-1 levels in adult 
patients after HSCT have been observed [11]. On the 
other hand, interleukins such as IL-6 and IL-1 are im-
plicated in bone loss through osteoclastic activation [12, 
13]. It has been reported that enhanced bone resorption 
following HSCT was related to the dose of administered 
steroids and the increase in IL-6 level. Recent studies 
have presented the OPG/RANKL/RANK system as the 
dominant, final mediator of osteoclastogenesis [14, 15]. 
RANKL is a member of the TNF ligand family. Osteo-
clast precursors express Receptor Activator of Nuclear 
Factor NF-κB (RANK), a TNF receptor family member, 
recognise RANKL through cell-to-cell interaction with 
osteoblast/stromal cells, and differentiate to prefusion 
osteoclasts. OPG is a soluble receptor for RANKL and 
acts as a decoy receptor in the RANK-RANKL signalling 
system [16, 17]. Some studies have shown that circulat-
ing osteoprotegerin and receptor activator of NF-kappa 
B ligand system are associated with bone metabolism 
[18, 19]. It was also suggested that interleukins may play 
an important role for post-BMT bone loss in adults [20], 
possibly via the RANKL pathway [21]. 
In children, normal values for BMD as well as in-
terleukins levels and OPG/RANKL/RANK system have 
not yet been well established, although it is clear that 
loss of bone density and increased risk of fracture is 
a significant issue in children after HSCT. 
The aim of this study was to assess the RANKL-OPG 
system, IGF-I, IL-6, and IL1β levels in children and ado-
lescents after HSCT, and to evaluate their association 
with bone mineral density.
Material and methods
Thirty five patients (15 girls and 20 boys, mean age 
8.48 ± 5.18 years) treated in the Transplantation Centre 
in the University Hospital in Krakow between 2008 and 
2010 were included in the study. The Local Ethical Com-
mittee of Jagiellonian University in Krakow approved 
the study. All participants and their parents gave their 
written, informed consent.
The patients were admitted due to different hae-
matological (nine patients with acute lymphoblastic 
leukaemia, four with acute myeloid leukaemia, and two 
patients with aplastic anaemia), oncologic (14 patients 
with solid tumours and one with Hodgkin’s disease) 
and non-malignant diseases (five patients with immu-
nodeficiency syndromes). 
Autologous haematopoietic stem cells transplan-
tation were performed in 14 patients. High-dose 
chemotherapy before autologous HSCT consisted of 
busulphan and melphalan in eight patients, and cyclo-
phosphamide, etoposide and melphalan in six patients. 
Twenty one patients were recipients of allogeneic 
haematopoietic transplants. Fourteen received grafts 
from matched related donors, and seven from matched 
unrelated donors. A conditioning regime included 
total body irradiation and etoposide in 14 patients, 
high-dose chemotherapy consisting of busulphan and 
cyclophosphamide in six patients, and fludarabine and 
melphalan in three patients. All patients after allogeneic 
transplantation received cyclosporine A as graft versus 
host disease prevention for 3–6 months. 
Anthropometrical measurements were made in all 
participants included in the study. Height was meas-
ured to the nearest centimetre using a rigid stadiometer. 
Weight was measured unclothed to the nearest 0.1 kg 
using a calibrated balance scale. Reference for Polish 
Children for the analysis of the obtained data were used 
[22]. The pubertal developmental stage of each patient 
was determined according to Tanner scale. 
Mean height SDS of patients was near mid-parental 
height SDS (up to 1 SD) and patients’ body mass was 
appropriate for their height (mean 89% of body mass 
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appropriate for the height). Nineteen patients were pre-
pubertal, 12 were during puberty, and four had finished 
pubertal development before inclusion in the study. 
Moreover a detailed analysis of all factors influenc-
ing bone remodelling such as other endocrine compli-
cations, renal function and drug administration was 
performed. One participant of this study was treated 
with recombinant growth hormone after diagnosis 
of growth hormone deficiency. Two girls received an 
oestrogen-progesterone replacement therapy due to 
hypergonadotrophic hypogonadism. Five patients 
received levothyroxine due to hypothyroidism and 
they were euthyrotic as were the remaining patients. 
All patients had normal serum levels of calcium and 
phosphorus. After HSCT they received vitamin D and 
calcium supplementation, however vitamin D level was 
not checked. All patients were encouraged to carry out 
regular physical activity, especially weight-bearing exer-
cises. None of them was treated with bisphosphonates.
Two patients were treated with steroids because of 
GVHD development after HSCT. No chronic inflamma-
tions were observed in the presented group of patients.
Blood samples were taken from the antecubital 
vein in the fasting state, at 8am. After clotting, blood 
samples were centrifuged and serum samples were 
stored at -80oC until the measurement of required 
parameters. Blood samples for measurement of the 
above-mentioned parameters were taken in the follow-
ing periods: before the HSCT procedure, on the trans-
plantation day, three months after HSCT, six months 
after HSCT, then annually after the transplantation. 
RANKL (IDS, Germany), OPG (IDS, Germany), and 
IL-1β (Diasource, Belgium) were measured by ELISA, 
IGF-I by RIA (Diasource, Belgium), and IL-6 by IRMA 
(Diasource, Belgium).
Total body bone mineral density (BMD) was 
evaluated using the dual energy X-ray absorptiometry 
method using Delfi W. Hologic Densitometer (USA). 
The evaluation of BMD was performed before HSCT, 
six months after, and then annually after HSCT.
Statistical calculations were performed using 
Statistica program (StatSoft, Inc, USA). Results were 
expressed as mean ± SD. SDS were used if necessary 
to remove age and gender dependence. Multiple re-
gression, Student’s t-test, and ANOVA with a post hoc 
Tukey’s test were used for analysis. In the performed 
analysis p < 0.05 was considered statistically significant.
Results 
The densitometry revealed negative Z-score values 
of total BMD of all assessed participants of the study. 
Z-score values of total BMD were significantly lower in 
patients with graft versus host disease (median –3.86) 
than others (median –1.16). Patients after autologous 
HSCT had significantly higher bone mineral den-
sity (0.876 ± 0.12 g/cm2) than patients after allogeneic 
transplantation (0.748 ± 0.04 g/cm2) (p = 0.03). Since 
the second year after autologous HSCT, bone mineral 
density (0.991 ± 0.05 g/cm2) was significantly (p = 0.05) 
higher compared to BMD before this time (0.761 ± 0.06 
g/cm2). In allogeneic patients, the variability of BMD 
values during all observation times was not statistically 
significant (p = 0.2). 
Mean values of serum concentrations of IL-6, IL-1β, 
OPG, RANKL, and SDS for IGF-1 levels of all patients 
are presented in Table I. The serum levels of IGF-I and 
IL-6 significantly changed after HSCT. The concentra-
tion of IGF-I significantly increased since the second 
year after transplantation and it approached the normal 
values for a child of this age. IL-6 levels were signifi-
cantly higher during the first 12 months after transplan-
tation with a peak in the sixth month, compared to its 
values before HSCT and the values two years after the 
Table I. Mean data ± SD of serum concentrations of interleukin 6 (IL-6), interleukin 1β (IL-1β), osteoprotegerin (OPG), 
Receptor Activator for Nuclear Factor κB ligand (RANKL), and z-SDS for insulin-like growth factor 1 (IGF-1) in patients after 
haematopoietic stem cell transplantation (HSCT) (*p < 0.05)
Tabela I. Średnie surowicze stężenia wraz z odchyleniami standardowymi dla interleukiny 6, interleukiny 1β, osteoprotegeryny, 
liganda aktywatora receptora jądrowego czynnika κB oraz uwzględniające wiek i płeć odchylenia standardowe dla 
insulinopodobnego czynnika wzrostu 1 u pacjentów po przeszczepieniu komórek krwiotwórczych (*p < 0.05)
Before HSCT HSCT day 3-M after HSCT 6-M after HSCT 1-Y after HSCT ≥ 2-Y after HSCT
z-SDS IGF-1 –2.62 ± 1.3 –2.67 ± 1.2 –2.6 ± 1.0 –1.8 ± 1.0 –2.12 ± 0.9 –0.89 ± 0.9*
IL-6 [pg/mL] 9.7 ± 7.2 20.2 ± 15.2 16.1 ± 8.2 21.3 ± 8.3 18.7 ± 23.7 8.27 ± 4.6*
IL-1β [pg/mL] 1.64 ± 3.0 0.2 ± 0.1 0.58 ± 1.2 0.2 ± 0.1 1.9 ± 4.5 1.3 ± 3.6
RANKL [pmol/L] 0.12 ± 0.2 0.12 ± 0.1 0.02 ± 0.01 0.02 ± 0.02 0.07 ± 0.1 0.04 ± 0.1
OPG [pmol/L] 4.66 ± 0.5 5.71 ± 2.9 6.62 ± 1.8 6.56 ± 2.1 4.9 ± 4.7 5.07 ± 1.3
*p < 0.05. HSCT — haematopoietic stem cell transplantation; z-SDS; IL-6 — interleukin 6; IL-1β — interleukin 1β, RANKL — Receptor Activator for Nuclear Factor κB 
ligand, OPG — osteoprotegerin
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procedure. Some changes of OPG and RANKL levels 
were observed after HSCT. Although not statistically 
significant, there was a tendency toward a decrease 
of RANKL and an increase of OPG values between 
three and six months after transplantation. Six months 
after HSCT, the mean RANKL values were statistically 
higher in patients after autologous than after allogeneic 
transplantation. On the other hand, the serum IGF-1 
levels in the autologous group were significantly lower 
than in allogeneic ones. The mean levels of IL-6, IL-1β, 
OPG did not differ between patients after auto- and 
allogeneic HSCT for samples taken in the same time 
after HSCT (Table II).
IL-6 level correlated positively with IL-1β concen-
tration at every moment of the study (Fig. 1). Both 
interleukins did not correlate with BMD, as well as with 
RANKL and OPG values. For both studied allogeneic 
and autologous groups, BMD correlated significantly 
with serum levels of RANKL (r = 0.624, p = 0.039) as 
well as with OPG/RANKL ratio (r = 0,683, p-0,020). For 
both groups, BMD correlated also with IGF-1 levels 
(Fig. 2). 
Discussion
Several studies have tried to explain the pathomecha-
nism of bone disorders in patients after HSCT, but the 
problem is still not completely understood. Although 
the peripheral mononuclear cells in the recipients are 
of donor origin, the bone marrow stromal cells are of 
recipient origin after bone marrow transplantation 
(BMT). It is known that the differentiation of bone 
marrow stromal cells into osteoblasts is impaired after 
BMT, and this contributes to post-BMT bone loss [20]. 
The growth factors produced by osteoblasts, includ-
ing IGF-1, play an important role in bone growth and 
osteogenesis [9]. A mouse model presented by Yakar 
et al. [10] demonstrated that a threshold concentra-
tion of circulating IGF-1 is necessary for normal bone 
growth and suggested that it plays a prominent role in 
the pathophysiology of osteoporosis. Moreover, IGF-1 
correlated positively with total bone, spinal density 
and bone resorption markers [23]. Salerno et al. [24] 
documented that allogeneic HSCT restores IGF-1 
production and linear growth in a SCID patient with 
abnormal growth hormone receptor signalling. This 
suggests that cells derived from haematopoietic stem 
cells may unexpectedly exert a significant role in IGF-
1 production. In our study we observed an increase 
of IGF-1 concentration since the second year after 
HSCT, when the graft was stable. Similar to the report 
of Salerno et al. [24], our data also suggests that cells 
derived from haematopoietic stem cells are involved 
in IGF-1 production. 
However, our observation could also suggest that 
at least two years are needed to rebuild bone marrow 
stromal cells which had been destroyed by a condition-
ing regime of high-dose chemo- and/or radiotherapy. 
Table II. Mean data ± SD of serum concentrations of interleukin 6 (IL-6), interleukin 1β (IL-1β), osteoprotegerin (OPG), 
Receptor Activator for Nuclear Factor κB ligand (RANKL), and z-SDS for insulin-like growth factor 1 (IGF-1) in patients six 
months after autologous and allogeneic haematopoietic stem cell transplantation (HSCT)
Tabela II. Średnie surowicze stężenia wraz z odchyleniami standardowymi  dla interleukiny 6, interleukiny 1β, osteoprotegeryny, 
liganda aktywatora receptora jądrowego czynnika κ B oraz uwzględniające wiek i płeć odchylenia standardowe dla insulino-
podobnego czynnika wzrostu 1 u pacjentów w 6 miesięcy po autologicznych i allogenicznych przeszczepieniach komórek
Autologous 
HSCT
Allogeneic 
HSCT
Normal
range*
p
No of patients 14 21
Age (years) 6.9 ± 5.1 8.9 ± 3.7 0.07
z-SDS IGF-I –2.7 ± 1.4 –1.8 ± 0.8 0.012
IL-6 [pg/mL] 13.1 ± 9.4 16.2 ±8.4 0–31
(3.27 ± 3.1)
0.19
IL-1β [pg/mL] 3.03 ± 4.9 4.99 ± 2.5 0–17
(2.6 ± 5.3)
0.25
RANKL [pmol/L] 0.17 ±0.1 0.05 ± 0.04 0–2
(0.43 ± 0.13)
0.001
OPG [pmol/L] 5.7 ± 1.5 5.9 ± 1.5 0–30
(1.8 ± 0.05)
0.38
*based on 2.5% to 97.5% percentiles. HSCT — haematopoietic stem cell transplantation; z-SDS; IL-6 — interleukin 6; IL-1β — interleukin 1β, RANKL — Receptor 
Activator for Nuclear Factor κB ligand, OPG — osteoprotegerin
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The positive correlation between IGF-1 and BMD in 
our study could suggest an important role of IGF-1 in 
osteogenesis and therefore in the pathophysiology of 
osteoporosis in childhood. This corresponds to previ-
ous reports regarding the data obtained in adults after 
HSCT [9, 21].
Some studies have indicated the possible role 
of the OPG/RANKL/RANK system in the patho-
physiological evolution of post-transplantational 
osteoporosis. Increases in the mean value of sRANKL 
level and the sRANKL/OPG ratio could indicate a 
negative balance in bone metabolism following BMT 
[25]. Short-term changes of the biochemical markers’ 
concentration in the post-transplantation period 
suggest a rapid impairment of bone formation and 
an increase in bone resorption [26]. Tae et al. [25] 
showed dynamic changes in the RANKL and OPG 
levels immediately during the post-BMT period, 
which were related to a decrease in bone formation 
and loss of lumbar spine bone mass density during 
the year following the BMT. In the present study, 
some changes of OPG and RANKL after HSCT has 
also been observed. Although not statistically sig-
nificant, there was a tendency towards a decrease 
of RANKL and an increase of OPG levels between 
three and six months after transplantation. This 
finding is in agreement with the data presented by 
Gandhi et al. [27] who reported that bone-specific 
alkaline phosphatase activity showed a significant 
initial decline one month after transplantation, but 
the activity returned to pre-transplant levels by the 
third month. The changes of the serum RANKL and 
OPG levels seem to precede the biological process 
of bone regeneration. Terpos et al. [28] showed that 
autologous stem cell transplantation normalises the 
abnormal bone resorption in multiple myeloma pa-
tients possibly through a decrease of RANKL/OPG 
ratio, while bone formation requires a longer period 
to return to normal [28]. 
The significant differences in IGF-I and RANKL 
levels in patients six months after allogeneic HSCT, 
as compared to autologous, could imply that chemo-
therapy conditioning rather than radiotherapy affects 
these parameters. In patients after allogeneic HSCT 
also immunological effects of transplanted donor cells 
on these parameters cannot be ruled out. Fabrega et 
al. [29] showed that a significant amount of OPG and 
RANKL is released in the early post-transplant period 
of liver transplantation and they tried to explain this 
phenomenon by an activation of the immune system 
caused by allograft.
A quite interesting finding of our study is the signifi-
cant correlation observed between RANKL concentra-
tions as well as OPG/RANKL ratio with BMD. This could 
suggest that not only circulating IGF-1 concentration 
but also RANKL level reflects bone density metabolism 
in childhood, but this hypothesis requires further study 
on a larger population.
One of the factors responsible for post-transplanta-
tion osteoporosis is administration of glucocortiocoids 
after HSCT. Long-term exposure to glucocorticoids 
results in a dose-dependent increase in serum RANKL 
concentration and the RANKL/OPG ratio, but not in 
the level of serum OPG [30]. Our patients treated with 
Figure 1. Correlation between serum interleukin 6 (IL-6) 
and interleukin 1β (IL-1β) in children and adolescents after 
haematopoietic stem cell transplantation
Rycina 1. Korelacja pomiędzy surowiczymi stężeniami 
interleukiny 6 i interleukiny 1β u  dzieci i młodzieży po 
przeszczepie komórek krwiotwórczych
Figure 2. Correlation between serum insulin-like growth factor 
1 (IGF-1) levels and bone mineral density (BMD) in children and 
adolescents after haematopoietic stem cell transplantation 
Rycina 2. Korelacja pomiędzy surowiczymi stężeniami insulino-
podobnego czynnika wzrostowego 1 i gęstością mineralną kości 
u dzieci i młodzieży po przeszczepie komórek krwiotwórczych
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steroids had the lowest Z-sore values of total BMD. A 
definitive statement on the effect of glucocorticoids 
on bone metabolism cannot be made due to the small 
number of patients receiving such treatment after HSCT. 
However, similarly to cyclosporine A used in GVHD 
prevention, glucocorticoids might be responsible for 
lower BMD of allogeneic patients as compared to au-
tologous ones [2]. 
In spite of immunosuppression, post-BMT bone loss 
is primarily related to gonadal dysfunction. Cytokines, 
especially interleukin-6, play an important role in the 
pathogenesis of postmenopausal osteoporosis related 
to oestrogen deficiency. Data on the pathogenetic role 
of cytokines in post-BMT bone loss is scarce. Lee et al. 
[31] reported an increase in bone marrow IL-6, which 
can induce bone resorption both alone and in concert 
with other bone-resorbing agents, during the immedi-
ate post-BMT period. There was a significant positive 
correlation between a serum bone resorption marker 
and bone marrow IL-6 levels following BMT, so it 
was suggested that the progressive increase in bone 
resorption is related to the increase in bone marrow 
IL-6 [31]. Polymorphism in the interleukin-6 gene is 
associated with bone mineral density in adolescents 
[32]. Two decades ago it was reported that interleukin-1 
beta stimulates resorption and inhibits bone formation 
both in vitro and in vivo [13]. Several years later it was 
shown that interleukin-1 alpha and interleukin-1 beta 
blockade prevents cartilage and bone destruction [33]. 
Il-1 beta is one of the suggested factors involved in 
bone remodelling regulation, acting as local effectors, 
possibly under the control of PTH [34]. Interleukin-1 
is essential for systemic inflammatory bone loss [35]. 
Interleukin-1 gene polymorphism is associated with 
bone mineral metabolism in rheumatoid arthritis [36]. 
We found a significant, positive correlation between 
IL-6 and IL-1β levels, however this does not allow us to 
hypothesise the association between circulating levels 
of both interleukins and bone mineral metabolism. Lack 
of correlation between interleukin and RANK-RANKL-
OPG system in our study could be explained by the 
age of the patient, as the majority of our patients were 
prepubertal so gonadal dysfunction did play any role 
in this period of life. 
Our study is the first clinical report on the correla-
tions between IGF-1, OPG/RANKL/RANK system, in-
terleukins, and BMD after HSCT performed in children. 
Present data indicates that factors influencing bone 
remodelling undergo dynamic changes in the post-
transplantation period in children and adolescents. It 
may be suggested that serum IGF-1 and RANKL could 
be predictors of bone metabolism after transplantation 
in paediatric patients, but these results require further 
study on a larger population. 
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